T
Todd E. DeFor
Researcher at University of Minnesota
Publications - 297
Citations - 19625
Todd E. DeFor is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 64, co-authored 288 publications receiving 17856 citations. Previous affiliations of Todd E. DeFor include City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood
Claudio G. Brunstein,Jonathan A. Gutman,Daniel J. Weisdorf,Ann E. Woolfrey,Todd E. DeFor,Ted Gooley,Michael R. Verneris,Frederick R. Appelbaum,John E. Wagner,Colleen Delaney +9 more
TL;DR: It is concluded that leukemia-free survival after dUCB transplantation is comparable with that observed after MRD and MUD transplantation and for patients without an available HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative.
Journal ArticleDOI
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Juliet N. Barker,Daniel J. Weisdorf,Todd E. DeFor,Bruce R. Blazar,Jeffrey S. Miller,John E. Wagner +5 more
TL;DR: It is demonstrated that 0-2 antigen mismatched UCB is sufficient to engraft most adults after reduced-intensity conditioning and is associated with a low incidence of severe acute GVHD.
Journal ArticleDOI
Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen–matched unrelated donor bone marrow: results of a matched-pair analysis
Juliet N. Barker,Stella M. Davies,Todd E. DeFor,Norma K.C. Ramsay,Daniel J. Weisdorf,John E. Wagner +5 more
TL;DR: It is suggested that despite increased HLA disparity, probabilities of engraftment, GVHD, and survival after UCB transplantation are comparable to those observed after HLA-matched BM transplantation, and UCB should be considered an acceptable alternative to HLA -mismatched BM for pediatric patients.
Journal ArticleDOI
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants
Stella M. Davies,Loredana Ruggieri,Todd E. DeFor,John E. Wagner,Daniel J. Weisdorf,Jeffrey S. Miller,Andrea Velardi,Bruce R. Blazar +7 more
TL;DR: The data show no advantage for KIR ligand incompatibility in this clinical setting as assessed by HLA-Bw4 and Hla-C alleles, and it is possible that there will be a benefit of NK cell alloreactivity if strategies of haploidentical transplantation are used: high stem cell doses, extensive T-cell depletion, and no postgrafting immune suppression.
Journal ArticleDOI
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
Shernan G. Holtan,Todd E. DeFor,Aleksandr Lazaryan,Nelli Bejanyan,Mukta Arora,Claudio G. Brunstein,Bruce R. Blazar,Margaret L. MacMillan,Daniel J. Weisdorf +8 more
TL;DR: A novel composite end point of GV HD-free/relapse-free survival (GRFS) in which events include grade 3-4 acute GVHD, systemic therapy-requiring chronic GVhd, relapse, or death in the first post-HCT year is examined.